

April 01, 2025

To, Listing/ Compliance Department BSE LTD. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001

**SCRIP CODE: 543748** 

Dear Sir/Madam,

To, Listing/ Compliance Department National Stock Exchange of India Limited "Exchange Plaza", Plot No. C/1, G Block, Bandra Kurla Complex,

Bandra (E), Mumbai – 400 051

SYMBOL: AARTIPHARM

Sub: Entering into an Addendum to the Subscription and Shareholders' Agreement

Ref: Regulation 30 of SEBI (LODR) Regulations,

2015 ('Listing Regulations')

Pursuant to Regulation 30 read with Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform the Exchanges that the Company ("APL") has executed an Addendum to the Subscription and Shareholders Agreement entered into between the Company and the Hemant Bandodkar & family (Bandodkars) pursuant to which Ganesh Polychem Limited (GPL) would be Joint Venture Company of APL w.e.f the close of business hours of 31st March 2025.

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is given in Annexure 'A' attached to this letter.

Please take the same on your records.

Thanking you,

Yours faithfully, For AARTI PHARMALABS LIMITED

JEEVAN MONDKAR COMPANY SECRETARY AND LEGAL HEAD ICSI M. NO. A22565

Encl.: a/a.



## **Annexure A**

| Sr.No | Particulars   | Details   |
|-------|---|---|
| 1     | Name(s) of parties with whom the agreement is entered   | Aarti Pharmalabs     Limited; and     Hemant Bandodkar &     Family (Bandodkars)  |
| 2     | Purpose of entering into the agreement  | Addendum to the Subscription & Shareholder's agreement  |
| 3     | Shareholding, if any, in the entity with whom the agreement is executed   | Not applicable  |
| 4     | Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc. | No special rights have been granted to any of the parties under the Agreement.  |
| 5     | Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship   | No. Bandodkars are not related to promoter / promoter group or any group companies of Aarti Pharmalabs Limited.   |
| 6     | Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms length"   | No.   |
| 7     | In case of issuance of shares to the parties, details of issue price, class of shares issued  | There is no fresh issuance of shares to any of the parties.   |
| 8     | Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.                        | None  |
| 9     | In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s):   | Agreement between APL and Bandodkars.   |
|       | a) name of parties to the agreement;  | Addendum to the Subscription &  |
|       | b) nature of the agreement.   | Shareholders' Agreement   |
|       | c) date of execution of the agreement;  | 31 <sup>st</sup> March 2025   |
|       | d) details of amendment and impact thereof or reasons of termination and impact thereof.  | GPL will be APL's Joint Venture. Wef 1-Apr-2025, APL will prepare and present its consolidated Financial statements following Equity Method of consolidation. |

